The Effect of Hepatic Insufficiency on the Safety and Pharmacokinetics of Paricalcitol (Zemplar®)

Background/Aims: Paricalcitol is highly protein bound, extensively metabolized and eliminated primarily by hepatobiliary excretion. This study was designed to determine if hepatic disease alters the pharmacokinetics or affects the safety of paricalcitol. Methods: Subjects with mild (n = 5) or modera...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Nephron. Clinical practice 2006-01, Vol.103 (3), p.c100-c105
Hauptverfasser:	Carr, Robert A., André, Amy K., Chen, Ping, Grabowski, Brian A., Chang, Min S., Locke, Charles S., Williams, Laura A., Chojkier, Mario
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Blood Proteins - metabolism Case-Control Studies Ergocalciferols - adverse effects Ergocalciferols - metabolism Ergocalciferols - pharmacokinetics Hepatic Insufficiency - metabolism Hepatic Insufficiency - physiopathology Humans Liver - physiopathology Male Middle Aged Original Paper Severity of Illness Index
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!